MA51287A - Analogues d'incrétine et leurs utilisations - Google Patents
Analogues d'incrétine et leurs utilisationsInfo
- Publication number
- MA51287A MA51287A MA051287A MA51287A MA51287A MA 51287 A MA51287 A MA 51287A MA 051287 A MA051287 A MA 051287A MA 51287 A MA51287 A MA 51287A MA 51287 A MA51287 A MA 51287A
- Authority
- MA
- Morocco
- Prior art keywords
- incretin
- analogues
- incretin analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Details Of Garments (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608644P | 2017-12-21 | 2017-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51287A true MA51287A (fr) | 2021-03-31 |
Family
ID=65003515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051287A MA51287A (fr) | 2017-12-21 | 2018-12-14 | Analogues d'incrétine et leurs utilisations |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11834486B2 (fr) |
| EP (1) | EP3727425A1 (fr) |
| JP (2) | JP6987993B2 (fr) |
| KR (1) | KR102440323B1 (fr) |
| CN (1) | CN111511387A (fr) |
| AR (1) | AR113487A1 (fr) |
| AU (1) | AU2018388895B2 (fr) |
| BR (1) | BR112020010410A2 (fr) |
| CA (1) | CA3084004C (fr) |
| CL (1) | CL2020001636A1 (fr) |
| CO (1) | CO2020006253A2 (fr) |
| CR (1) | CR20200256A (fr) |
| DO (1) | DOP2020000124A (fr) |
| EA (1) | EA202091284A1 (fr) |
| EC (1) | ECSP20032306A (fr) |
| IL (2) | IL325352A (fr) |
| JO (1) | JOP20200136B1 (fr) |
| MA (1) | MA51287A (fr) |
| MX (2) | MX2020006547A (fr) |
| MY (1) | MY199545A (fr) |
| PE (1) | PE20200926A1 (fr) |
| PH (1) | PH12020551024A1 (fr) |
| SG (1) | SG11202004359YA (fr) |
| TW (2) | TWI767095B (fr) |
| UA (1) | UA127589C2 (fr) |
| WO (1) | WO2019125929A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| KR20240051304A (ko) * | 2018-07-23 | 2024-04-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
| AR119471A1 (es) | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| KR102812908B1 (ko) | 2019-08-19 | 2025-05-28 | 일라이 릴리 앤드 캄파니 | 인크레틴 유사체의 제조 방법 |
| AR120714A1 (es) * | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
| IL294955A (en) * | 2020-01-23 | 2022-09-01 | Lilly Co Eli | Cobalt-agonist gip/glp1 compounds |
| JP2023535382A (ja) * | 2020-07-17 | 2023-08-17 | ハンミ ファーマシューティカル カンパニー リミテッド | 三重作用性持続型結合体又は三重作用剤を含む組合せ物の治療学的用途 |
| EP4197560A4 (fr) * | 2020-08-14 | 2025-11-26 | Hanmi Pharmaceutical Co Ltd | Composition pharmaceutique comprenant un conjugué persistant de triple activateur utilisé comme principe actif |
| US20230391845A1 (en) | 2020-10-30 | 2023-12-07 | Novo Nordisk A/S | Glp-1, gip and glucagon receptor triple agonists |
| TWI837615B (zh) | 2021-03-23 | 2024-04-01 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
| WO2022247701A1 (fr) | 2021-05-26 | 2022-12-01 | 联邦生物科技(珠海横琴)有限公司 | Multi-agoniste et son utilisation |
| WO2022268029A1 (fr) * | 2021-06-21 | 2022-12-29 | 广东东阳光药业有限公司 | Agoniste triple pour récepteurs glp-1, gcg et gip |
| CA3223313A1 (fr) | 2021-06-23 | 2022-12-29 | Eli Lilly And Company | Methodes d'utilisation et compositions comprenant un analogue d'incretine |
| AU2022392980B2 (en) * | 2021-11-19 | 2025-12-18 | Jiangsu Deyuan Pharmaceutical Co., Ltd. | Stapled peptide and use thereof |
| CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| AU2023348864A1 (en) * | 2022-09-28 | 2025-03-20 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gcg/gip triple-receptor agonist and use thereof |
| JP2026502943A (ja) | 2022-12-30 | 2026-01-27 | アルギファルマ エーエス | 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法 |
| US20240270821A1 (en) | 2023-01-31 | 2024-08-15 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
| WO2024213022A1 (fr) * | 2023-04-11 | 2024-10-17 | 上海多米瑞生物技术有限公司 | Analogues d'incrétine et leur procédé de préparation, et utilisation |
| CN120329412A (zh) * | 2023-11-06 | 2025-07-18 | 成都奥达生物科技有限公司 | 一种三激动剂化合物 |
| CN120349393A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种三激动剂化合物 |
| CN119241684B (zh) * | 2024-11-22 | 2025-02-25 | 徐州医科大学 | 一种肠促胰岛素类似物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127880A (zh) | 2009-03-27 | 2014-11-05 | 葛兰素集团有限公司 | 药用融合体和缀合物 |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| WO2015067715A2 (fr) * | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Composés agonistes doubles de gip et glp-1 et procédés associés |
| CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| TWI582109B (zh) | 2015-01-09 | 2017-05-11 | 美國禮來大藥廠 | Ｇｉｐ及ｇｌｐ－１共促效劑化合物 |
| WO2016198624A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip |
| TWI700291B (zh) | 2015-06-22 | 2020-08-01 | 美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| SG11201805586SA (en) | 2015-12-31 | 2018-07-30 | Hanmi Pharmaceutical Co Ltd | Triple glucagon/glp-1/gip receptor agonist |
| EP3217027A1 (fr) | 2016-03-08 | 2017-09-13 | HILTI Aktiengesellschaft | Élement de revetement large destine a entourer une tige d'ancrage |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
-
2018
- 2018-12-05 TW TW107143623A patent/TWI767095B/zh active
- 2018-12-05 TW TW111118551A patent/TWI810937B/zh active
- 2018-12-06 AR ARP180103573A patent/AR113487A1/es unknown
- 2018-12-14 BR BR112020010410-8A patent/BR112020010410A2/pt unknown
- 2018-12-14 MY MYPI2020003206A patent/MY199545A/en unknown
- 2018-12-14 WO PCT/US2018/065605 patent/WO2019125929A1/fr not_active Ceased
- 2018-12-14 CR CR20200256A patent/CR20200256A/es unknown
- 2018-12-14 JP JP2020532952A patent/JP6987993B2/ja active Active
- 2018-12-14 MX MX2020006547A patent/MX2020006547A/es unknown
- 2018-12-14 AU AU2018388895A patent/AU2018388895B2/en active Active
- 2018-12-14 PE PE2020000800A patent/PE20200926A1/es unknown
- 2018-12-14 EA EA202091284A patent/EA202091284A1/ru unknown
- 2018-12-14 EP EP18830614.6A patent/EP3727425A1/fr active Pending
- 2018-12-14 US US16/769,015 patent/US11834486B2/en active Active
- 2018-12-14 KR KR1020207017385A patent/KR102440323B1/ko active Active
- 2018-12-14 CA CA3084004A patent/CA3084004C/fr active Active
- 2018-12-14 CN CN201880082714.8A patent/CN111511387A/zh active Pending
- 2018-12-14 UA UAA202002893A patent/UA127589C2/uk unknown
- 2018-12-14 IL IL325352A patent/IL325352A/en unknown
- 2018-12-14 SG SG11202004359YA patent/SG11202004359YA/en unknown
- 2018-12-14 MA MA051287A patent/MA51287A/fr unknown
-
2020
- 2020-05-22 CO CONC2020/0006253A patent/CO2020006253A2/es unknown
- 2020-06-02 JO JOJO/P/2020/0136A patent/JOP20200136B1/ar active
- 2020-06-17 IL IL275469A patent/IL275469B1/en unknown
- 2020-06-17 DO DO2020000124A patent/DOP2020000124A/es unknown
- 2020-06-17 PH PH12020551024A patent/PH12020551024A1/en unknown
- 2020-06-17 CL CL2020001636A patent/CL2020001636A1/es unknown
- 2020-06-19 EC ECSENADI202032306A patent/ECSP20032306A/es unknown
- 2020-07-13 MX MX2025003745A patent/MX2025003745A/es unknown
-
2021
- 2021-12-01 JP JP2021195036A patent/JP2022043082A/ja not_active Withdrawn
-
2023
- 2023-10-30 US US18/497,390 patent/US20240190936A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
| EP3817822A4 (fr) | Agents de dégradation de protéines et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3749318A4 (fr) | Raltitrexed gamma-polyglutamaté et utilisations associées | |
| EP3749315A4 (fr) | Raltitrexed alpha-polyglutamaté et utilisations associées | |
| EP3471727A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3472129A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3600273A4 (fr) | Inhibiteurs de cd73 et leurs utilisations | |
| EP3749314A4 (fr) | Méthotrexate alpha-polyglutamaté et utilisations associées | |
| EP3445365A4 (fr) | Inhibiteurs d'ezh2 et leurs utilisations | |
| EP3383916A4 (fr) | Anticorps anti-cd73 et leurs utilisations | |
| EP3504243A4 (fr) | Anticorps anti-tim-3 et leurs utilisations | |
| EP3389702A4 (fr) | Anticorps anti-lag-3 et leurs utilisations | |
| EP3413816A4 (fr) | Compositions hydratantes et utilisations associées | |
| EP3426288A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3344275A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3790861A4 (fr) | Compositions sénolytiques et utilisations associées | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| EP2968443A4 (fr) | Analogues d'hepcidine et leurs utilisations | |
| EP3439741A4 (fr) | Antagonistes d'alk7 et leurs utilisations | |
| EP3294318A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3283516A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3471726A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations |